Redefining Triple-Negative Breast Cancer: Understanding the Clinical Evidence That Will Transform Practice
Highlights From the 2017 ESMO Congress
My Take: Integrating Biosimilars Into an Oncology Practice
Hokusai VTE-Cancer Study: Edoxaban vs Dalteparin for VTE in Adult Cancer Patients
SELECT-D: Dalteparin vs Rivaroxaban Anticoagulation Therapy for Patients With Cancer at Risk of VTE Recurrence
Conference CoverageEducationClinicalThoughtDecision SupportCCO Live EventsSlidesets & Resources
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Clinical Care Options, LLC. All Rights Reserved.